Munich Biotechnology tests tumour diagnostic agent
This article was originally published in Clinica
Executive Summary
German firm Munich Biotechnology has begun a clinical trial to investigate the use of its tumour diagnostic agent during the surgery of patients with cancer of the head and neck.